1LLY : Eli Lilly's Options: A Look at What the Big Money is Thinking
The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...
Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Josh Gottheimer
Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed ...
pharmaphorum4d
Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challenge
Eli Lilly’s crop of new products propelled ... s chief financial officer Josh Smiley on the company’s results call, adding that Trulicity “grew faster than the market, hosting an increase ...
Eli Lilly Unusual Options Activity
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...
Is Eli Lilly and Company (LLY) the Best Pharma Dividend Stock to Buy In 2024?
We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...
Eli Lilly: Still Expensive As Earnings Near, But Not Worthy Of A Downgrade
Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.
Rep. Josh Gottheimer Sells Eli Lilly and Company (NYSE:LLY) Stock
Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on January 14th, the Representative disclosed that they had sold between ...